News


2021-04-16

Nanolyze has been granted support from Vinnova

The analytical software is under development and Vinnova has granted support for this project within the program Innovativa Startups.

​Read more


2020-09-02

Team member Mattias Sjöberg presents his licentiate thesis

We are proud to announce that our gifted research engineer Mattias Sjöberg is presenting his licentiate thesis entitled Characterization of biological nanoparticles using evanescent field sensing

​Read more


2020-07-06

Parkinson's disease cell damage studied using Nanolyze technologies

​In sufferers of Parkinson's disease, clumps of α-synuclein (alpha-synuclein), sometimes known as the ‘Parkinson’s protein’, are found in the brain. These destroy cell membranes, eventually resulting in cell death. Now, Nanolyze technologies reveals how the composition of cell membranes seems to be a decisive factor for how small quantities of α-synuclein cause damage.

Read more 


2020-06-22

Nanolyze AB is founded

The company Nanolyze has been founded with Nils Löfgren as CEO and GU Ventures being the major investor.

Read more 

Publications


Effective Refractive Index and Lipid Content of Extracellular Vesicles Revealed Using Optical Waveguide Scattering and Fluorescence Microscopy

Langmuir June 20, 2018, 34(29): 8522-8531, 2018

Full article


Evanescent Light-Scattering Microscopy for Label-Free Interfacial Imaging: From Single Sub-100 nm Vesicles to Live Cells

ACS Nano 2015, 9, 12, 11849-11862, October 30, 2015

Abstract


Single-vesicle imaging reveals lipid-selective and stepwise membrane disruption by monomeric α-synuclein

PNAS June 23, 2020 117 (25) 14178-14186

Full article


Two-dimensional flow nanometry of biological nanoparticles for accurate determination of their size and emission intensity

Nature Communications volume 7, Article number: 12956, 2016

Full article



Nanolyze has been granted support from Vinnova

2021-04-16

Nanolyze is in an intense period of product development and the analyzing software is a key component of our instrument. We allow sub-microscopic analysis at single particle level without the need for labelling and the patented core technology is based on waveguide analysis. To make all the unique capabilities available for efficient analysis of nanoparticles, there is a need for intuitive and powerful software. This software is under development and Vinnova has granted support for this project within the program Innovativa Startups.


“The grant from Vinnova helps us moving forward at an increased speed and thus make our technology more valuable to the users at an earlier stage”, says CEO Nils Löfgren.


Nanolyze is at the doorstep of delivering the first units of the instrument to pilot users. The first delivery will be without the software, but already at the end of June, the first prototype versions will be delivered. Without the software it is still possible to start applying the technology to new applications are reveal hidden properties of biological nanoparticles. However, when the instrument is completed with software, it will start reaching the full potential of usability.


← Back

Team member Mattias Sjöberg presents his licentiate thesis

2020-09-02

Title: Characterization of biological nanoparticles using evanescent field sensing

Location: Zoom

Time: 2020-09-02 13:00-15:00

​Main Supervisor and examiner: Fredrik Höök
Reviewer: Tapani Viitala


Read abstract here


← Back


Parkinson's disease cell damage studied using Nanolyze technologies

2020-07-06

The new study, recently published in the journal PNAS, focuses on two different types of membrane-like vesicles. One of them is made of lipids that are often found in synaptic vesicles, the other contained lipids related to mitochondrial membranes.

The researchers found that the Parkinson’s protein would bind to both vesicle types, but only caused structural changes to the mitochondrial-like vesicles, which deformed asymmetrically and leaked their contents.

“Now we have developed a method which is sensitive enough to observe how α-synuclein interacts with individual model vesicles, which are ‘capsules’ of lipids that can be used as mimics of the membranes found in cells. In our study, we observed that α-synuclein binds to – and destroys – mitochondrial-like membranes, but there was no destruction of the membranes of synaptic-like vesicles. The damage occurs at very low, nanomolar concentration, where the protein is only present as monomers – non-aggregated proteins. Such low protein concentration has been hard to study before but the reactions we have detected now could be a crucial step in the course of the disease,” says Pernilla Wittung-Stafshede, Professor of Chemical Biology at the Department of Biology and Biological Engineering.


Read full article here


← Back

Nanolyze AB is founded

2020-06-22

Nanolyze has been founded as a spinout from the Gothenburg Sensor Devices (GSD). IP rights are inherited from GSD and Nanolyze will replace GSD in the research collaboration FoRmulaEx. Nanolyze will focus on development and commercialisation of technologies for nanoparticle sorting and analysis, which has been a part of the GSD technology portfolio.

Nils Löfgren will be heading the company as CEO and his long and mixed experience within life science from academia, small product companies, and multinational consultancy business will be a great asset for the company.

The technologies are developed by researchers at Nano and Biophysics at Chalmers University of Technology, and several of the key inventors are co-founders together with GU Ventures, Nils Löfgren, and the people behind GSD.

Professor Fredrik Höök at Chalmers is the main founder and is part of the board. His long experience within the field of analyzing nanoparticles will be one of the keys for the success of Nanolyze according to Nils Löfgren. The deep application insight and his broad network with a strong position in the field will be valuable, and his experience from developing QCMD and the company QSense is a great help.


← Back